Evolve BioSystems manufactures Evivo, a proprietary probiotic comprised of activated B. infantis EVC001 aimed at resolving infant gut dysbiosis (Newborn Gut Deficiency). Studies cited by the company show Evivo guides critical development of infants' digestive and immune systems by restoring a missing bacterium to the infant gut microbiome. The company reports that Evivo reduces potentially pathogenic bacteria by 80 percent and significantly reduces intestinal inflammation. Evolve BioSystems announced it completed a first close in a $55 million Series D round of funding. That first close was led by Cargill and Manna Tree. The company is based in Davis, CA. Evolve BioSystems is a Davis, CA–based company that develops products to establish, restore, and maintain a healthy gut microbiome. Its flagship infant probiotic product, Evivo, is an activated form of Bifidobacterium longum subsp. infantis (B. infantis EVC001). The company completed a $40M Series C financing to support growth. Evolve plans to use the funds to expand Evivo availability in the US and worldwide, develop products for age segments beyond infants, and accelerate efforts to bring a microbiome diagnostic test to market. A spin-out from the Foods for Health Institute at the University of California, Davis, the company is led by CEO Tim Brown. The Gates Foundation will expand its partnership with Evolve to investigate Evivo's potential to help infants suffering from severe acute malnutrition and to study the role of B. infantis alongside breastfeeding in supporting healthy growth and preventing infection. Evolve BioSystems develops products to establish, restore, and maintain a healthy human gut microbiome, with a focus on newborns. Its core offerings include activated probiotic and prebiotic products intended to restore the infant gut microbiome to its natural state and support proper metabolic and immune development. The company is a spin-out from the Foods for Health Institute at the University of California, Davis and is led by CEO Dr. David Kyle. Evolve is applying its discovery platform to address gut dysbiosis across the human life cycle and in various animal species. It is undertaking further clinical studies to build out its microbiome-based solutions. The company completed a $20M Series B financing to support clinical activities, operational expansion, product launches, and animal health product development. Evolve BioSystems is a Davis, California–based microbiotics company developing proprietary probiotic and prebiotic solutions to address dysbiosis in the infant microbiome. Led by CEO Dr. David Kyle, the company is undertaking multiple clinical trials to validate its assets. Evolve is a spin-out from the Foods For Health Institute at the University of California, Davis, and previously closed a seed funding round in 2014. The company completed a $9M Series A to support ongoing clinical activities, operational expansion, and preparations for commercial launch. Its product focus targets microbiome disruption resulting from pre-term birth, Caesarean-section deliveries, and exclusive use of infant formula.

Total raised

$124M

Funding rounds

4

Latest round

Series D

Latest activity

Feb 2021